A randomized clinical trial of nafoxidine, a non-steroidal oestrogen antagonist, and ethinyloestradiol in postmenopausal patients with advanced breast cancer produced objective remissions in 31 00 of 49 women receiving nafoxidine and in 140o of 49 receiving ethinyloestradiol. The difference in remission rates was almost significant (0 05<P<0-10). Life-threatening complications were more frequent with ethinyloestradiol than with nafoxidine but the latter produced specific toxic reactions on skin and hair that may limit its practical usefulness. Synthetic oestrogen antagonists may occupy a privileged place in the treatment of breast cancer, and other representatives of this new class of compounds should be accurately assessed in randomized clinical trials.
Introduction
Nafoxidine hydrochloride is a non-steroidal oestrogen antagonist. It inhibits the oestradiol-induced increase of uterine weight in rats which have undergone oophorectomy. Yet when given alone to these animals it produces a weak uterotrophic effect of its own.' It prevents oestradiol retention in the uterus, both in vivo and in vitro.' These effects are thought to be mediated through the operation of the tissue-specific oestrogen receptors. Oestrogens first bind to the cytoplasmic receptors, and the resulting complex is then translocated into the cell nucleus where it triggers various metabolic reactions.4 Nafoxidine, like other antioestrogens, produces a similar sequence of events, but with a much lower potency. [5] [6] [7] Recent data suggest that nafoxidine may operate in different w;ays: it displaced for protracted periods the receptors from the cytoplasm into the nucleus, thereby producing both antioestrogenic and weak oestrogenic effects. 8 Moreover, nafoxidine has a biphasic action at the molecular level: at low concentrations it induces translocation of the nafoxidine-receptor complex into the nucleus, but at higher concentrations it inhib-ts this process as well as the translocation of the oestradiol-receptor complex. This inhibition might account for both its "antioestrogenic" and its "autoinhibitory" effects. 9 Nafoxidine also prevents oestradiol retention in vitro in the DMBA-induced, hormone-dependent, rat mammary carcinoma3 and in human breast cancers.'0 Moteover, it has antitumour effects on the rat mammary carcinoma. It prevents tumour induction" and inhibits tumour growth." 12 table I ) had received previous hormonal or cytotoxic therapy or both, but all such therapy had been discontinued at least six weeks before the trial started, and no lesion had regressed in the meantime. No patient had received hormonal implants within two years of the study. The use of drugs which depressed hypothalamic activity was discouraged to avoid possible stimulation of prolactin secretion.16 X rays were given when necessary to localized lesions which caused a high risk to the patient of complications such as bone fracture or spinal cord compression. The lesions so treated and those nearby them which received significant irradiation were not used as criteria of response to hormonal therapy.
A prerequisite for admission of patients into the study was the presence of objective criteria for assessing response to treatment. Pleural effusion was not accepted as a criterion. Patients with central nervous system or "massive" liver involvement (more than a third of liver tissue replaced by tumour) were not admitted to the trial because they are notoriously resistant to endocrine treatments. Moribund patients were also excluded.
ASSESSMENT OF PATIENT S RESPONSES
Initially all patients were given a thorough clinical examination, with x-ray examinations of the chest and skeleton and routine haematological and blood chemistry assessments. The soft-tissue lesions were measured with a caliper and photographed whenever possible. An isotopic liver scintigram was obtained in cases with suspected liver involvement. During treatment all the initial studies were repeated every six weeks until the response to treatment could be assessed.
Hormonal treatment was given for at least six weeks unless major intolerance occurred. Nafoxidine (U-li, 100A, Upjohn (1-( 2-[p- (3,4- (table II) . The response rate to a given treatment was similar in all categories of menopausal age, disease-free interval, dominant site of lesions, and number of sites involved. Recalcification of bone lytic lesions occurred less often with both nafoxidine and ethinyloestradiol than regression of soft tissue or visceral lesions but even by pooling the results of the two treatments the difference was not statistically significant (X2=3-05; 0-05<P<0-10).
Side Effects.-Side effects of nafoxidine consisted mainly of ichtyosis (11 cases) which increased with duration of treatment. Though non-pruriginous this skin change was sometimes extremely severe and made it difficult to pursue the treatment. Phototoxic reaction of the skin, without significant burn, occurred in most cases on exposure, even indirect, to sunlight. Partial loss of hair was recorded in six patients. Other complications were nausea and vomiting (mild in two cases, severe in one), hypercalcaemia (one case), liver toxicity characterized by raised serum transaminase levels (one), bilateral thrombophlebitis of both legs without previous history of thrombotic disease (one), and mild thrombocytopenia in a patient with bone marrow involvement (one). These complications led to discontinuation of treatment in three cases. The side effects of ethinyloestradiol were nausea and vomiting (mild in one case, severe in four cases), hypercalcaemia (three cases), uncontrolled fluid retention (one), and acute dyspnoea (one). In eight cases treatment had to be stopped because of these complications.
Discussion
These results confirm our finding that nafoxidine is effective in the treatment of postmenopausal patients with advanced breast cancer.14 The total experience of the E.O.R.T.C. Group in our previous and two present trials (see Engelsman et al.,8 this issue) yields a rate of nafoxidine-induced objective remissions of 28% (30 remissions out of 108 patients treated). This rate is almost identical to that (33%) recently reported by Bloom and Boesen.19 Both treatment groups were similar, which indicated that no significant bias occurred during the randomization process. Though nafoxidine yielded a distinctly higher remission rate than ethinyloestradiol the difference fell short of statistical significance and, therefore, was merely suggestive of nafoxidine's higher efficacy. Nafoxidine's apparent superiority may have been due, at least in part, to there being fewer premature interruptions of treatment on nafoxidine than on ethinyloestradiol. Since most interruptions resulted from major drug intolerance, however, this explanation would leave intact the practical superiority of nafoxidine though it is likely to level the biological therapeutic efficacy of the two drugs. Remission rates on either drug did not seem influenced by factors reported to be of prognostic significance in the treatment of advanced breast cancer,17 but this may have been due to the small numbers of patients.
Apart from the eight cases ofmajor intolerance ethinyloestradiol produced no significant untoward effects. In contrast, nafoxidine produced fewer life-threatening reactions but produced very specific side effects. Ichtyosis was sometimes severe enough to make it difficult to pursue treatment. Partial hair loss was a significant complaint. Photoxicity of the skin, which occurred in nearly all patients on mild or even indirect exposure to sunlight was inconvenient during the summer.
As an oestrogen antagonist nafoxidine is one of a new class of compounds which have proved to be active in the treatment of breast cancer. Our results suggest that in this disease it is one of the most effective hormone-related drugs though its practical usefulness is limited by its toxicity on skin and hair. Other oestrogen antagonists such as tamoxifen (I.C.I. 46474) have recently been reported to be therapeutically active in breast cancer and devoid of major side effects.20 21 It is important to assess the exact therapeutic value of these compounds in controlled clinical trials.
